Filing Details
- Accession Number:
- 0001209191-11-056355
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-11-16 14:47:54
- Reporting Period:
- 2011-11-15
- Filing Date:
- 2011-11-16
- Accepted Time:
- 2011-11-16 14:47:54
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1294596 | Nancy Wysenski | C/O Vertex Pharmaceuticals Incorporated 130 Waverly St Cambridge MA 02139 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2011-11-15 | 606 | $29.77 | 32,935 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $29.77 (range $29.65 to $29.95).
- Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.